Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Armitage, Emily G ^a,d   Kotze, Helen L ^a   Allwood, J William ^a,e   Dunn, Warwick B ^a,b,f   Goodacre, Royston ^a   Williams, Kaye J ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSIDAD SAN PABLO CEU   (Spain)

^e SCOTTISH CROP RESEARCH INSTITUTE   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYDROXYPROLINE; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN;

CELL HYPOXIA; HCT 116 CELL LINE; HUMAN; HYPOXIA; METABOLISM; METABOLOMICS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BIOMARKERS; CELL HYPOXIA; CELL LINE, TUMOR; HCT116 CELLS; HUMANS; HYDROXYPROLINE; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; OXYGEN; SIGNAL TRANSDUCTION;

EID: 84945937413     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15649     Document Type: Article

References (33)

1. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20, 5197-5206; doi: 10.1093/emboj/20.18.5197 (2001).
2. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Gene. Dev. 16, 1466-1471; doi: 10.1101/gad.991402 (2002).
3. Ruan, K., Song, G. & Ouyang, G. L. Role of Hypoxia in the Hallmarks of Human Cancer. J. Cell. Biochem. 107, 1053-1062, doi: 10.1002/jcb.22214 (2009).
4. Armitage, E. G., Kotze, H. L. & Williams, K. J. Correlation-based Network Analysis of Cancer Metabolism: A New Systems Biology Approach in Metabolomics. (Springer, 2014).
5. Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J.Clin. Invest. 118, 3930-3942; doi: 10.1172/jci36843 (2008).
6. Troy, H. et al. Metabolic profiling of hypoxia-inducible factor-1 beta-deficient and wild type Hepa-1 cells: effects of hypoxia measured by H-1 magnetic resonance spectroscopy. Metabolomics 1, 293-303; doi: 10.1007/s11306-005-0009-8 (2005).
7. Armitage, E. G. & Barbas, C. Metabolomics in cancer biomarker discovery: Current trends and future perspectives. J. Pharmaceut. Biomed. 87, 1-11; doi: 10.1016/j.jpba.2013.08.041 (2014).
8. Roberts, D. L. et al. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Brit. J. Cancer 101, 1290-1297; doi: 10.1038/sj.bjc.6605311 (2009).
9. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 465, 966-966 doi: 10.1038/nature09132 (2010).
10. Duncan, C. G. et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 22(12), 2339-2355 doi: 10.1101/gr.132738.111 (2012).
11. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27-30; doi: 10.1093/ nar/28.1.27 (2000).
12. Tarhonskya, H. et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat. Commun. 5 doi: 10.1038/ncomms4423
13. Oldham, W. M. et al. Hypoxia-mediated increases in L-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metabolism 22(2), 291-303 doi: http://dx.doi.org/10.1016/j.cmet.2015.06.021 (2015).
14. Intlekofer, A. M. et al. Hypoxia induces production of L-2-hydroxyglutarate. Cell Metabolism 22(2), 304-311 doi: http://dx.doi. org/10.1016/j.cmet.2015.06.023 (2015).
15. Golinska, M. et al. Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC cancer 11(198), doi: 10.1186/1471-2407-11-198 (2011)
16. Kotze, H. L. et al. A novel untargeted metabolomics correlation-based network analysis incorporating human metabolic reconstructions. BMC Syst. Biol. 7, 107 doi: 10710.1186/1752-0509-7-107 (2013).
17. Patra, K. C. et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer cell 24, 213-228 doi: 10.1016/j.ccr.2013.06.014 (2013).
18. Mathupala, S. P., Rempel, A. & Pedersen, P. L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type 2 hexokinase gene to hypoxic conditions. J. Biol. Chem. 276(46), 43407-43412 doi: 10.1074/jbc. M108181200 (2001)
19. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 doi: 10.1038/nrc1187 (2003).
20. Hoffman, E. C. et al. Cloning of a factor required for activity of the AH (Dioxin) receptor. Science 252, 954-958; doi: 10.1126/ science.1852076 (1991).
21. Maxwell, P. H. et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. P. Natl. Acad. Sci. USA 94, 8104-8109; doi: 10.1073/pnas.94.15.8104 (1997).
22. Brown, L. M. et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol. Pharmacol. 69, 411-418; doi: 10.1124/mol.105.015743 (2006).
23. Burrows, N. et al. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr.-Relat. Cancer 17, 61-72; doi: 10.1677/erc-08-0251 (2010).
24. Begley, P. et al. Development and Performance of a Gas Chromatography-Time-of-Flight Mass Spectrometry Analysis for Large-Scale Nontargeted Metabolomic Studies of Human Serum. Anal. Chem. 81, 7038-7046; doi: 10.1021/ac9011599 (2009).
25. Dunn, W. B. et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060-1083; doi: 10.1038/nprot.2011.335 (2011).
26. Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis. Metabolomics 3, 211-221; doi: 10.1007/ s11306-007-0082-2 (2007).
27. Babushok, V. I. et al. Development of a database of gas chromatographic retention properties of organic compounds. J. Chrom. A 1157, 414-421; doi: 10.1016/j.chroma.2007.05.044 (2007).
28. Kopka, J. et al. GMD@CSB.DB: the Golm Metabolome Database. Bioinformatics 21; doi: 10.1093/bioinformatics/bti236 (2005).
29. Fiehn, O. et al. The metabolomics standards initiative (MSI). Metabolomics 3, 175-178; doi: 10.1007/s11306-007-0070-6 (2007).
30. Steuer, R., Morgenthal, K., Weckwerth, W. & Selbig, J. A gentle guide to the analysis of metabolomic data. Meth. Mol. Biol. 358, 105-126; doi: 10.1007/978-1-59745-244-1-7 (2007).
31. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate-a practical approach to multiple testing. J. R. Stat. Soc. B. 57, 289-300 (1995).
32. Goodacre, R. et al. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics 3, 231-241; doi: 10.1007/s11306-007-0081-3 (2007).
33. Ma, H. W. et al. The Edinburgh human metabolic network reconstruction and its functional analysis. Mol. Sys. Biol. 3; doi: 10.1038/msb4100177 (2007).